Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

MLA

Biagio Ricciuti, Md, et al. “Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.” JTO Clinical and Research Reports, vol. 1, no. 4, Nov. 2020. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2020.100074.

APA

Biagio Ricciuti, M., Abdul Rafeh Naqash, M., Jarushka Naidoo, M., Kartik Sehgal, M., Adam Miller, M., Kenneth Kehl, M. M., Deepti Venkatraman, M., Jacob Sands, M., Giuseppe Lamberti, M., Gonzalo Recondo, M., PhD, Jiajia Zhang, M., Shravanti Macherla, M., Sameer Baig, M., Paul Walker, M., Deepa Rangachari, M., Justin F. Gainor, M., Daniel B. Costa, M., Naiyer Rizvi, M., Lynette M. Sholl, M., … Mark M. Awad, M., PhD. (2020). Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clinical and Research Reports, 1(4). https://doi.org/10.1016/j.jtocrr.2020.100074

Chicago

Biagio Ricciuti, Md, Md Abdul Rafeh Naqash, Md Jarushka Naidoo, Md Kartik Sehgal, Md Adam Miller, Md, Mph Kenneth Kehl, Mph Deepti Venkatraman, et al. 2020. “Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.” JTO Clinical and Research Reports 1 (4). doi:10.1016/j.jtocrr.2020.100074.